Journal of International Medical Research · 2012 · 30 citations · 20 references
MedicineCancer BiologyOncologyMetastasisSignal TransductionTumor ProgressionAngiogenesisAngiogenesis In CancerCancer Cell SignalingMetastatic Breast CancerMetastatic Signaling PathwaysTumor InvasionBreast Cancer ProgressionExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingInfiltrationMalignant Breast TumorsMetastasis PathologyMetastatic Breast Cancer BiologyTumor Cell Invasiveness
OBJECTIVE: The presence of mesothelin (encoded by the mesothelin [MSLN] gene) in breast cancer is associated with tumour infiltration of the lymph node. This study evaluated whether MSLN overexpression promotes breast cancer cell invasiveness and metastasis. METHODS: This study evaluated the effects of overexpression of MSLN on extracellular signal-regulated kinase (ERK1/2) and matrix metalloproteinase (MMP)-9 levels, and the invasiveness and angiogenesis of the breast cancer cell line MCF-7 in vitro, and on MCF-7-derived tumour development in vivo. RESULTS: MSLN overexpression significantly increased ERK1/2 and MMP9 protein levels and activity, and the invasive and angiogenic capability of MCF-7 cells, in vitro. Inhibition of ERK1/2 suppressed MMP-9 and the invasive and angiogenic capability of MSLN overexpressing MCF-7 cells. MSLN overexpression also increased MCF-7-derived tumour metastasis in vivo. CONCLUSION: MSLN overexpression promoted the invasive potential of MCF-7 cells through ERK1/2-dependent upregulation of MMP-9; this association may have contributed to metastasis of MCF-7 cells in vivo. Mesothelin may be a useful biomarker for cancer progression and a novel therapeutic or chemopreventive target in human breast cancer.
20
Pedram Argani, Christine A. Iacobuzio–Donahue, Byungwoo Ryu et al. · PubMed · 2001 · 578 citations
Raffit Hassan, Susie Bullock, Ahalya Premkumar et al. · Clinical Cancer Research · 2007 · 381 citations · Full text
Pharmacy, Oncology, Pharmacology +16
Dung T. Le, Dirk G. Brockstedt, Ran Nir‐Paz et al. · Clinical Cancer Research · 2011 · 368 citations · Full text
Life Sciences, Immunology, Oncology +17